

AMENDMENTS

IN THE SPECIFICATION:

Page 18, line 7, please amend the paragraph starting on this line as follows:

D¹ (Amended) Also, the present invention offers a compound consisting of ribonucleic acid extracted from yeast, for example a *Saccharomyces cerevisiae* or a *Candida utilis*. Preferably, the ribonucleic acid has a nitrogen content of more than 14.5% by weight and a phosphorus content of more than 8.5% by weight, more preferably a nitrogen content of more than 14.7% by weight and a phosphorus content of more than 8.6% by weight, even more preferably a nitrogen content of more than 15.0% by weight and a phosphorus content of more than 9.0% by weight.

IN THE CLAIMS:

Please cancel claim 7 without prejudice or disclaimer.

Please amend claims 1, 10-11, 20-22 and 39-45 as follows:

Sub G1
D2
1. (Twice Amended) A method for the prevention or treatment of inflammation or inflammatory-related disorder selected from the group consisting of infarct, arthritis, diabetes, arteriosclerosis, tumor, hepatitis, infection, and neuro-degenerate diseases, comprising administering to a mammal in need of such treatment a composition comprising total yeast ribonucleic acid and a pharmaceutically acceptable vehicle, carrier, or diluent, said composition comprising said ribonucleic acid in an amount effective to ameliorate symptoms of inflammation or inflammatory-related disorder, wherein said composition is administered so that said ribonucleic acid is present into the mammal's

^{D²}
~~blood.~~

^{D³} 10. (Amended) A method in accordance with claim 1, wherein said ribonucleic acid has a nitrogen content of more than 14.5% by weight.

11. (Amended) A method in accordance with claim 1, wherein said ribonucleic acid has a phosphorus content of more than 8.5% by weight.

^{S²} ^{D⁴} ~~20. (Three Times Amended) A pharmaceutical composition for the treatment or the prevention of inflammation or inflammatory-related disorder, comprising total yeast ribonucleic acid and a pharmaceutically acceptable vehicle, carrier, or diluent, wherein said ribonucleic acid has a nitrogen content of at least 14.7% by weight and a phosphorus content of at least 8.6% by weight.~~

21. (Amended) A pharmaceutical composition in accordance with claim 20, wherein said ribonucleic acid has a nitrogen content is more than 15.16% by weight.

22. (Amended) A pharmaceutical composition in accordance with claim 20, wherein said ribonucleic acid has a phosphorus content of more than 9.05% by weight.

^{Jul 6 52} 39. (Amended) The method of claim 1, wherein the composition comprises at least about 14.7% by weight of nitrogen and at least about 8.6% by weight of phosphorus.

^{DS} 40. (Amended) The method of claim 1, wherein the composition comprises at least about 15.16% by weight of nitrogen and at least about 8.6% by weight of phosphorus.

41. (Amended) The method of claim 1, wherein the composition comprises at least about 15.49% by weight of nitrogen and at least about 9.05% by weight of phosphorus.

42. (Amended) The method of claim 1, wherein the composition comprises more than 15.0% by weight of nitrogen and more than 9.0% by weight of phosphorus.

43. (Amended) The composition of claim 20, comprising at least about 15.16% by weight of nitrogen and at least about 8.6% by weight of phosphorus.

44. (Amended) The composition of claim 20, comprising at least about 15.49% by weight of nitrogen and at least about 9.05% by weight of phosphorus.

45. (Amended) The composition of claim 20, comprising more than 15.0% by weight of nitrogen and more than 9.0% by weight of phosphorus.

Please add new claims 46-55 as follows:

46. The method of claim 1, wherein said inflammation or inflammatory-related disorder is infarct.

47. The method of claim 1, wherein said inflammation or inflammatory-related disorder is arthritis.

48. The method of claim 1, wherein said inflammation or inflammatory-related disorder is diabetes.

49. The method of claim 1, wherein said inflammation or inflammatory-related disorder is arteriosclerosis.

50. The method of claim 1, wherein said inflammation or inflammatory-related disorder is tumor.

51. The method of claim 1, wherein said inflammation or inflammatory-related disorder is hepatitis.

52. The method of claim 1, wherein said inflammation or inflammatory-related disorder is

infection.

53. The method of claim 1, wherein said inflammation or inflammatory-related disorder is a neuro-degenerate disease.

54. The method of claim 53, wherein said neuro-degenerate disease is selected from Parkinson's disease, Alzheimer's disease, multiple sclerosis, and encephalitis.

D⁶ Sub 7 55. A method for the prevention or treatment of inflammation or inflammatory-related disorder, comprising administering to a mammal in need of such treatment a composition comprising total yeast ribonucleic acid and a pharmaceutically acceptable vehicle, carrier, or diluent, said composition comprising said ribonucleic acid in an amount effective to ameliorate symptoms of inflammation or inflammatory-related disorder, wherein said composition is administered so that said ribonucleic acid is present into the mammal's blood, and wherein said ribonucleic acid has a nitrogen content of at least 14.7% by weight and a phosphorus content of at least 8.6% by weight.